about
Gut Microbiota and Lifestyle Interventions in NAFLDBenefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients.Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis.The effects of onion consumption on treatment of metabolic, histologic, and inflammatory features of nonalcoholic fatty liver disease.Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial.Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USANonalcoholic fatty liver disease - current status and future directions.Creatine supplementation as a possible new therapeutic approach for fatty liver disease: early findings.Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease.Lipid droplets and liver disease: from basic biology to clinical implications.SAF score and mortality in NAFLD after up to 41 years of follow-up.Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: Pathology and beyond.Pharmacokinetic and safety evaluation of MB12066, an NQO1 substrate.Virgin coconut oil reverses hepatic steatosis by restoring redox homeostasis and lipid metabolism in male Wistar rats.Editorial: progress towards a simple tool for screening for hepatic steatosis in the general population.Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells.Curcumin and hemopressin treatment attenuates cholestasis-induced liver fibrosis in rats: role of CB1 receptors.Folate and B12 Levels Correlate with Histological Severity in NASH Patients.Hypoxic Signaling and Cholesterol Lipotoxicity in Fatty Liver Disease Progression.Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl-CoA desaturase-1, lipase activity, leptin and resistin
P2860
Q26749783-E467BD9C-5472-48CF-AB36-8FF341EDCF95Q33573638-B0EC5770-A558-41F1-9B65-CB04BBFEA401Q33799384-BB69AAA6-72CB-4C0E-865B-6A881E1CDBD9Q37119409-4AEC51D2-A868-4544-839B-ED3829E61FA6Q37541501-0E86F40C-AA24-4272-95CB-36088E9F7900Q37728503-368DC9CB-2CDE-4E98-819C-485DC464D691Q38592767-95BDF8E0-EEB0-4120-983E-7FF1F5117392Q38718576-1F6AF9AB-174E-4BC3-B717-93A1E651043EQ39140524-51CDC117-5C5D-47D7-AA5A-7AC3EC14D3C2Q39253589-8208D70B-9665-47F9-A26E-DB2FB26300DAQ39402697-4CB9F1DB-7D91-4B91-B6B1-FE0C3F5BA45DQ41821872-5E362F23-FB47-46FE-96B7-A01EBD32D3D2Q42736026-465251A5-8F1C-4227-86DC-9E1E1BDEAFE9Q48141279-81CBB204-4DD5-4F42-8C6D-F5A52C36CDA2Q48291741-CC8ADF61-2E2C-48FF-82EA-423658BE7630Q50136712-EEC16014-77CD-4BE0-94B1-EBE8D126BADFQ50201534-6529603C-C6F3-4BDD-8E2A-72E1D7BD2CD0Q53308324-8DF77ED3-DD69-4A70-B7EA-0BBFAF71ED54Q54972685-91E1EF68-5233-4245-8FAB-F441C78163E7Q55425011-556D09C1-E141-493E-827C-3B5410E175DAQ58802792-D988E23C-939A-4A5C-853A-645325EBEFD5
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Nonalcoholic fatty liver disease: new treatments
@ast
Nonalcoholic fatty liver disease: new treatments
@en
Nonalcoholic fatty liver disease: new treatments
@nl
type
label
Nonalcoholic fatty liver disease: new treatments
@ast
Nonalcoholic fatty liver disease: new treatments
@en
Nonalcoholic fatty liver disease: new treatments
@nl
prefLabel
Nonalcoholic fatty liver disease: new treatments
@ast
Nonalcoholic fatty liver disease: new treatments
@en
Nonalcoholic fatty liver disease: new treatments
@nl
P2860
P921
P3181
P1476
Nonalcoholic fatty liver disease: new treatments
@en
P2093
Christopher P Day
Timothy Hardy
P2860
P304
P3181
P356
10.1097/MOG.0000000000000175
P407
P5008
P577
2015-05-01T00:00:00Z